GSK Expands Share Buyback Program with Recent Purchase

The latest announcement is out from GlaxoSmithKline ( (GB:GSK) ).

GSK has announced the purchase of 170,000 of its own ordinary shares as part of an ongoing buyback program, facilitated through BNP Paribas. This transaction is part of a larger strategy initiated on September 30, 2025, which has seen the company acquire a total of 7,989,000 shares. These shares will be held in treasury, impacting the total number of voting rights and potentially influencing shareholder interest calculations under regulatory guidelines.

The most recent analyst rating on (GB:GSK) stock is a Sell with a £15.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.

Spark’s Take on GB:GSK Stock

According to Spark, TipRanks’ AI Analyst, GB:GSK is a Outperform.

GlaxoSmithKline’s strong financial performance and positive earnings call sentiment are the most significant factors driving the stock score. The company’s robust growth in specialty medicines and successful R&D efforts contribute positively. Technical analysis supports a bullish outlook, while valuation remains reasonable with an attractive dividend yield. Challenges in the U.S. vaccines market and clinical trial delays are noted but do not significantly detract from the overall positive outlook.

To see Spark’s full report on GB:GSK stock, click here.

More about GlaxoSmithKline

GlaxoSmithKline (GSK) is a leading pharmaceutical company that specializes in the development and production of vaccines, medicines, and consumer healthcare products. The company operates globally, focusing on areas such as respiratory, HIV, immuno-inflammation, and oncology.

Average Trading Volume: 8,258,510

Technical Sentiment Signal: Buy

Current Market Cap: £71.86B

For detailed information about GSK stock, go to TipRanks’ Stock Analysis page.